Diffuse gliomas are the most common malignant brain tumours in adults and include glioblastomas and World Health Organization (WHO) grade II and grade III tumours (sometimes referred to as lower-grade gliomas). Genetic tumour profiling is used to classify disease and guide therapy 1,2 , but involves brain surgery for tissue collection; repeated tumour biopsies may be necessary for accurate genotyping over the course of the disease 3-10 . While the detection of circulating tumour DNA (ctDNA) in the blood of patients with primary brain tumours remains challenging 11,12 , sequencing of ctDNA from the cerebrospinal fluid (CSF) may provide an alternative way to genotype gliomas with lower morbidity and cost 13,14 . We therefore evaluated the representation of the glioma genome in CSF from 85 patients with gliomas who underwent a lumbar puncture because they showed neurological signs or symptoms. Here we show that tumour-derived DNA was detected in CSF from 42 out of 85 patients (49.4%) and was associated with disease burden and adverse outcome. The genomic landscape of glioma in the CSF included a broad spectrum of genetic alterations and closely resembled the genomes of tumour biopsies. Alterations that occur early during tumorigenesis, such as co-deletion of chromosome arms 1p and 19q (1p/19q codeletion) and mutations in the metabolic genes isocitrate dehydrogenase 1 (IDH1) or IDH2 1,2 , were shared in all matched ctDNA-positive CSF-tumour pairs, whereas growth factor receptor signalling pathways showed considerable evolution. The ability to monitor the evolution of the glioma genome through a minimally invasive technique could advance the clinical development and use of genotype-directed therapies for glioma, one of the most aggressive human cancers.
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hypermutation, the combination of genetic alterations that defined the LGG subtype were congruent between the CSF and tumour (Extended Data Fig. 4 , patients [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Mutations were also shared between the CSF and tumour in all twenty (100%) patients with GBMs without DNA hypermutation (Extended Data Fig. 4 , patients [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] .
Further analysis of CSF ctDNA revealed a broad spectrum of protein-coding mutations, copy number alterations (CNAs), promoter mutations, and structural rearrangements. The most commonly observed alterations included mutations within the TERT promoter, the protein-coding regions of TP53, and the catalytic domain of IDH1 as well as deletions of CDKN2A and CDKN2B, amplifications of the gene for epidermal growth factor receptor (EGFR), and the in-frame EGFR-variant III deletion (Fig. 1a ).
CSF ctDNA from 5 out of 42 patients with glioma (12%; Fig. 1a , asterisks) showed a markedly higher mutation rate and harboured a signature (G:C→A:T transitions) that suggests prior exposure to alkylating agents [18] [19] [20] (Extended Data Fig. 5 ). All five patients had received temozolomide before CSF collection. The median mutation rate in CSF ctDNA was 4.90 mutations per Mb. This rate is higher than the reported mutation rate in The Cancer Genome Atlas (TCGA) for the LGG exome (0.7-0.8 per Mb) 3 or the GBM exome (2.2 per Mb) 21 , but not different from the mutation rate in our glioma tumour biopsies previously sequenced with the same gene panel (Fig. 1b , MSK-IMPACT tissue cohort; 4.46 per Mb). This observation may be partially related to the more advanced disease of our patients and the enrichment of frequently mutated genes in MSK-IMPACT. Overall, the frequency of genetic alterations in CSF ctDNA mirrored the distribution of genetic alterations in glioma biopsies taken at the Memorial Sloan Kettering (MSK) Cancer Center (Fig. 1c ).
To determine whether mutations detected in the CSF were also present in the plasma, we sequenced plasma cell-free DNA (cfDNA) from 19 patients with gliomas who were positive for CSF ctDNA using a high-sensitivity capture-based next-generation sequencing assay (average raw sequence coverage >18,000×). This assay, while more targeted than MSK-IMPACT, encompassed at least one CSF mutation in each of the 19 patients, and 211 in total. We detected no mutations in plasma cfDNA from 16 out of 19 patients (84%; Supplementary Table 3 ). A total of 35 mutations were detected in the remaining three patients, including 32 from a single patient with a hypermutated tumour. The average variant allele fraction of these 35 mutations was very low in plasma (0.58%), compared to 23.96% in the CSF (Wilcoxon rank-sum test comparing allele fractions, P = 5.821 × 10 -11 ; Supplementary  Table 4 ). All three patients with positive plasma ctDNA had radiographic evidence of disseminated disease within the CNS and one of these patients (patient 11) later developed metastatic GBM (with bone and lymph node involvement). These data show that CSF is a more frequent reservoir of tumour DNA than plasma in patients with glioma. It also suggests that tumour DNA is shed from the tumour directly into the CSF, rather than reaching it indirectly through the plasma.
Sequential tumour biopsies in patients with glioma have uncovered considerable evolution of the cancer genome during the course of the disease, with only 33-73% of genetic alterations being shared between 
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initial and recurrent tumours from the same patient [3] [4] [5] [6] [7] [8] [9] [10] . In our 30 CSFtumour pairs without DNA hypermutation, the percentage of shared mutations varied considerably across samples (0-100%; Fig. 2a ), with a median 81.7% shared mutation rate. In patients with hypermutated tumours, shared mutations were considerably less common (3-49%; Fig. 2b) , with a median 19.6% shared mutation rate (Supplementary Table 5 ). The majority of mutations that were clonal in tissue were also present in CSF, even in patients with DNA hypermutation. By contrast, subclonal mutations were less likely to be shared in CSF (Fig. 2c ).
We also examined the concordance between contemporaneously collected CSF replicates and tumour-CSF pairs. Six patients in our study underwent placement of a ventriculo-peritoneal shunt for the treatment of hydrocephalus within three weeks of the initial lumbar puncture. Despite being collected from different anatomical locations within the CNS, the genomic profiles of these CSF replicates were highly concordant ( Fig. 2d ), even in patients with DNA hypermutation (Extended Data Fig. 6 ). Five patients in our study underwent a tumour resection within three weeks of CSF collection, and these patients showed near-identical genetic profiles in CSF and tumour tissue ( Fig. 2e ).
As the interval between tumour and CSF collection increased, we observed greater divergence of the genetic profiles, in particular for genes encoding members of growth factor signalling pathways ( Fig. 2f , Extended Data Fig. 7 ). This discordance followed a pattern of convergent evolution, with later samples showing other genetic alterations within the same gene or related signalling pathway. For example, the initial tumour biopsy from patient 25 harboured a high-level EGFR amplification and EGFR missense mutation, whereas a later CSF sample revealed amplification and mutation of the platelet-derived growth factor receptor alpha gene (PDGFRA) without evidence of the original EGFR alteration ( Fig. 2g) . Similarly, the initial tumour profile of patient 28 showed an activating mutation in PIK3CA (E545K), whereas a later tumour biopsy showed amplifications of MET and PDGFRA and a subsequent CSF sample retained the MET amplification and acquired a MYC amplification while losing the PDGFRA amplification (Extended Data Fig. 8a ). In LGGs, truncal alterations (IDH1, TP53 and ATRX) persisted throughout the disease course, but later samples contained additional mutations in glioma core pathways (Extended Data Fig. 8b ), a pattern consistent with branched evolution of the LGG genome.
Our study shows that tumour-derived DNA in CSF from patients with glioma provides a comprehensive and genetically faithful representation of the tumour genome at the time of the CSF collection. The frequency and type of alterations in the CSF closely resembled the genomic landscape of diffuse glioma, as defined in large oncogenomic studies 2, 16, 22 , and we observed high concordance between CSF and tumour DNA in patients who underwent both lumbar puncture and neurosurgical tumour resection within a few weeks. Any divergence between CSF and tumour genomes within the same patient followed the pattern of genomic evolution that has been reported in studies of sequential tumour biopsies. This evolution is characterized by the persistence of truncal genetic alterations (IDH1, 1p/19q codeletion, TP53, TERT, ATRX) and by convergent and branched evolution within glioma core pathways, in particular growth factor receptor pathways [3] [4] [5] [6] [7] [8] [9] [10] . Performing a lumbar puncture in patients with a brain tumour is usually safe and is done routinely for certain brain tumours as part of the staging criteria (for example, CNS lymphoma, medulloblastoma, germ cell tumours). In patients who have a tumour that cannot be approached surgically, a lumbar puncture offers an opportunity to obtain a molecular signature and potentially a definitive diagnosis. In patients in whom tumours recur, a lumbar puncture is a simpler and safer procedure than a second craniotomy for another tumour 01  07  15  21  22  06  08  11  20  25  10  17  02  03  23  14  19  28  30  04  18  09  26  29  16  24  27  12  13 No. of SNVs and indels Shown is the presence (blue) versus absence (white) of selected mutations in matched CSF-tumour pairs (n = 30, non-hypermutated). MSK cancer cohort; n = 553. g, Representative example for convergent evolution. Shown is the disease course of patient 25, who has GBM. MRIs (T2weighted fluid-attenuated inversion recovery (FLAIR)) are shown from the initial tumour resection (left) and at the time of CSF collection (right). The CSF sample collected at recurrence showed a new PDGFRA amplification and mutation and loss of the previously detected EGFR amplification and EGFR (G719C) mutation (copy number plots shown). Diamond, tumour sample profiled; circle, CSF sample profiled. Heat map variant allelic frequency scale shown.
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sample. However, shedding of tumour DNA into the CSF does not appear to be a universal property of diffuse glioma, even in previously treated patients. Our data suggest that the presence of ctDNA in the CSF may be an early indicator of progression in glioma. Further studies are needed to determine when tumour-derived DNA first becomes detectable in the CSF. By demonstrating the accuracy and frequency with which important mutational changes can be detected through CSF profiling, our work provides a framework for such studies.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-019-0882-3.
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METHODS
Patients.
Our study includes CSF and tumour samples from 85 patients who were treated for glioma at Memorial Sloan Kettering (MSK) Cancer Center from January 2015 to April 2017. All patients had received treatment for glioma before CSF collection, including surgery (85/85; 100%), radiation (84/85; 99%), and at least one systemic tumour-directed chemotherapy (81/85 95%). For 19/85 patients, we isolated ctDNA from plasma within four weeks of CSF collection to compare sequencing results between blood and CSF. We used a previously published sequencing cohort that included 553 MSK glioma samples from 512 patients 23, 24 to benchmark our CSF findings in patients with glioma against a larger number of glioma tumour biopsies sequenced with the same platform. All patients signed statements of informed consent under protocols approved by the MSK Institutional Review Board. Magnetic resonance imaging. All patients underwent brain MRIs as indicated by standard of care with standard sequences including axial T1-weighted, T2-weighted FLAIR and contrast T1-weighted images. Brain MRIs before and directly after the initial resection were reviewed by an experienced neuroradiologist without knowledge of the CSF ctDNA results. To calculate the extent of resection, the entire lesion was manually segmented using Aquarius iNtuition (Tera Recon) using axial contrast-enhanced T1-weighted images for enhancing lesions and axial FLAIR images for non-enhancing lesions. The process was repeated for the postoperative scans, with the volumes reported in cm 3 . The extent of resection was calculated for 63 patients with median 6 days between scans (range, 1-45). The remaining 22 patients were missing preoperative and/or postoperative scans. Brain MRIs that were performed closest to the CSF collection date were also reviewed by a neuroradiologist without knowledge of the CSF ctDNA results. Standard response assessment in neuro-oncology (RANO) criteria were applied to determine tumour burden (SPD) and radiographic progression 25 . The presence or absence of radiographic signs of tumour spread to subependymal, pial and leptomeningeal sites was also documented. In a binary manner, subependymal spread was determined to be present when the edge of the enhancing lesion extended to the subependymal margin of any ventricle. Similarly, pial spread was determined to be present when the edge of the enhancing lesion extended to any pial surface of the brain, and leptomeningeal spread when the enhancing lesion involved any subarachnoid space (for example, in a sulcus or fissure). CSF collection. CSF collections were performed as part of standard of care. CSF was collected by lumbar puncture in 82/85 (96%) patients. Additional CSF samples were collected during VP shunt placement or intraoperatively. Isolation of ctDNA. Freshly collected CSF was stored at 4 °C until centrifugation (1,400 r.p.m., 5 min, 4 °C). CSF supernatants were transferred into cryotubes and stored in 3.5-ml aliquots at −80 °C. Immediately before use, CSF (3.5 ml) was thawed in a waterbath at 37 °C. The QIAsymphony SP system (QIAGEN) was used for DNA extraction using two kits throughout the duration of the study: the QIAsymphony DSP Virus/Pathogen Midi Kit (937055) and the QIAsymphony DSP Circulating DNA Kit (937556). No differences in ctDNA performance were observed between the two kits.
Whole blood was collected in cell-free DNA BCT tubes (STRECK, 218962). Samples were centrifuged in two steps to isolate cell-free plasma. First, whole blood was centrifuged at 800g for 10 min (ambient temperature). The plasma was then separated from the red blood cells and centrifuged at 18,000g for 10 min (ambient temperature). Cell-free plasma (3.5 ml) was stored at −80 °C until the time of ctDNA extraction with the QIAsymphony DSP Virus/Pathogen Midi Kit or DSP Circulating DNA Kit. Isolation of tumour and germline DNA. Isolation of tumour DNA from formalin-fixed and paraffin-embedded (FFPE) tumours was performed using published protocols 24 . Of the 42 patients in whom ctDNA was detected in the CSF, 36 had residual tumour tissue and germline DNA for targeted sequencing. These 36 'matched' cases were used for the determination of genetic alterations that were shared between CSF and tumour. (In these 'matched pair' comparisons, we refer to tumour biopsy-derived DNA as 'tissue' to distinguish biopsy-derived tumour DNA from CSF-derived tumour DNA.) Targeted capture and sequencing. All CSF ctDNA samples were subjected to molecular analysis using the MSK-IMPACT assay, a custom FDA-authorized next-generation sequencing-based assay 15 that captures all protein-coding exons of 410 cancer-associated genes as well as 46 introns from 17 recurrently rearranged genes. Tumour DNA was sequenced using one of three iterations of IMPACT (IMPACT 341, IMPACT 410, or IMPACT 468) 24 . A genetically matched normal sample was used in 73/85 (86%) of cases. In patients without a genetically matched normal sample, variants were called against a single pool of unmatched normal samples, and variants were further filtered if the minor allele frequency was >1% in the 1000 Genomes cohort 26 , as these are more likely to be common population polymorphisms than somatic mutations. The current framework can be found at https://github.com/rhshah/IMPACT-Pipeline. Copy number variation was identified by analysing sequence coverage of targeted regions in a tumour sample in comparison to a standard diploid normal sample after performing sample-wide locally estimated scatterplot smoothing (LOESS) normalization for GC percentage across exons and normalizing for global differences in 'on-target' sequence coverage, as previously described 15 . All candidate somatic mutations, indels and structural aberrations were filtered, annotated using in-house tools, and manually reviewed using the Integrative Genomics Viewer 27 .
Plasma cfDNA samples were sequenced using a separate custom capture-based next-generation sequencing assay composed of one or more exons in 129 genes in MSK-IMPACT. Plasma cfDNA libraries were prepared using adapters with duplex unique molecular indexes (UMIs) to allow replicate reads from the same original template molecule to be collapsed in an error-free consensus sequence. Duplex UMIs enabled the construction of consensus sequences involving reads from both strands of the original molecule. Samples were sequenced to a raw coverage of >18,000× and a median unique coverage of 1,032×. Mutations previously detected in CSF were determined to be present in plasma cfDNA if they were supported by two or more duplex consensus reads. Comparison of genomic alterations in CSF and tumour. For concordance analysis of matched tumour-CSF pairs (n = 36), mutations were designated as either 'called' or 'present' . Called mutations were independently detected without any prior knowledge using clinically validated filters (total depth ≥ 20, variant allele depth ≥ 8 and variant allele frequency ≥ 2% for known mutational hotspots; total depth ≥ 20, variant allele depth ≥ 10 and variant allele frequency ≥ 5% for novel mutations). For all mutations called in either the tumour or the CSF, a secondary mutation analysis was performed for all other samples collected from the same patient, in which less stringent criteria were applied to detect the full compilation of SNVs. Mutations were called as present if variant allele depth ≥ 2 and variant allele frequency ≥ 1%. If these criteria were not met a mutation was marked as not present and considered to be limited to the tumour or the CSF. For the matched pair analysis, the tumour used was the closest tumour sequenced to the time of CSF collection. In patients with multiple CSF collections, we prioritized CSF samples that met the following criteria: (1) at least one mutation called in CSF; (2) CSF collected through lumbar puncture (that is, rather than during VP-shunt placement or intra-operatively); (3) highest sequence coverage; (4) shortest interval between CSF and tumour collection. Clonality analysis. We determined total, allele-specific, and integer DNA copy number genome-wide using the FACETS algorithm in all cases 28 . Allelic imbalance (including tumour-specific loss of heterozygosity) was determined from a change in the zygosity of heterozygous SNPs. We then defined the presence of genome doubling (GD) in samples for which the majority of the genome (>50%) contained multiple copies from the same parent/allele. Gene-level copy number was assigned from spanning segments of integer copy number data in each tumour. Homozygous deletion was determined from regions of total copy number of zero. Amplifications were those regions of total integer copy number greater than 5 or 6 in diploid and GD cases, respectively. Partial deletions (with intragenic breakpoints) were called whereas partial amplifications were not. Statistical analysis. Associations between ctDNA positivity and patient and treatment characteristics were assessed using nonparametric tests by either Wilcoxon rank-sum test or Fisher's exact test. Wilcoxon rank-sum test was used for the continuous variables and Fischer's exact test was used for the categorical variables. All statistical tests were two-sided with α ≤ 0.05 for statistical significance. To assess the association between CSF ctDNA positivity and overall survival, we performed a multivariable Cox model which included CSF ctDNA positivity and further adjusted for per cent extent of resection at original diagnosis, tumour burden at CSF collection, and IDH status. Follow-up time was calculated from time of CSF collection until death or last follow-up. Deaths were treated as events in the model and those who were alive at last follow-up were censored. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
All genomic results and associated clinical data for all patients in this study are publically available in the cBioPortal for Cancer Genomics at the following URL: http:// www.cbioportal.org/study?id=glioma_msk_2018. The MSK-IMPACT data analysis pipeline can be found here: https://github.com/rhshah/IMPACT-Pipeline. The source data for Table 1 and Extended Data Fig. 1 are available in Supplementary  Table 1 . The source data for the multivariable analysis (Extended Data Table 2 ) are available in Supplementary Table 2 . The source data for the matched pair analysis (Fig. 2a, b) 
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Extended Data Fig. 4 | Concordance between CSF and tumour in glioma subtype-defining genes. Shown are combinations of genetic alterations (LGG signatures) that are consistently congruent between the CSF and tumour (10/10). This was also the case in glioblastoma (20/20) . 
Extended Data Table 2 | Results from multivariable model for overall survival from the time of CSF collection CSF positivity was significantly associated with an increased rate of death from the time of CSF collection in an analysis that also accounted for the following variables: (1) per cent extent of resection at diagnosis; (2) tumour burden at the time of CSF collection; and (3) IDH status. n = 63 biologically independent samples. This number comprises n = 33 samples from CSF ctDNA-positive patients and n = 30 samples from CSF ctDNA-negative patients. The statistical tests used for the analysis were two-sided Wald tests. HR, hazard ratio; CI, confidence interval.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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Data collection
Sequence data for all CSF samples were generated in the MSK research sequencing core (IGO) in the Center for Molecular Oncology. Tumor sequence data for comparison were generated in the MSK clinical sequencing laboratory in the Department of Pathology and were obtained from the cBioPortal for Cancer Genomics (http://cbioportal.org/msk-impact).
Data analysis
The MSK-IMPACT data analysis pipeline can be found here: https://github.com/rhshah/IMPACT-Pipeline and is composed entirely of open source software. Multivariable survival analysis was performed using the PHREG procedure in SAS (Cary, NC) to implement Cox regression modeling, a standard statistical modeling technique not unique to SAS.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
nature research | reporting summary
April 2018
Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Data Availability: All genomic results and associated clinical data for all patients in this study are publically available in the cBioPortal for Cancer Genomics at the following URL: http://www.cbioportal.org/study?id=glioma_msk_2018
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Sample size
No sample size calculation was performed for this retrospective analysis, however all consecutive samples within 1/12/15-4/5/2017 were obtained. The sample size was sufficient since we were able to detect associations between tumor-derived DNA in CSF with both disease burden and adverse outcome.
Data exclusions The complete patient cohort consisted of 85 patients on whom all analyses were based with the exception of the multivariable Cox regression model. This model was based on a subset of 63 patients and is the only analysis where exclusion criteria were applied. Due to study design, 22 patients were excluded because the original tumor resection had been performed at an outside hospital and MRIs were not available. To ensure there were no differences in the complete patient cohort (n=85) and the subset on whom the multivariable Cox regression model was based (n=63), we compared the two groups on overall survival experience as well as all covariables in the model: CSF positivity, IDH status, percent extent of resection at diagnosis, and tumor burden at LP/CSF. There were no statistically significant differences between the two groups indicating that the subset of patients on whom the Cox regression model was based was comparable to the complete patient cohort.
Replication
For multiple patients in our study, a contemporaneous tumor biopsy or second CSF collection was available for comparisons with the CSF ctDNA sample. This data is included in Figure 2 and shows the reproducibility of our assay.
Randomization This was not a setting in which randomization was required since there was no intervention being assessed. Samples from all comers during a specific date range were assessed for signal.
Blinding
Conventional blinding was not used in our design since no intervention was being assessed. However, we note in the Methods section that: "Brain MRIs prior to and directly following the initial resection were reviewed by an experienced neuroradiologist without knowledge of the CSF ctDNA results."
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